Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIT Regimen Schedules in Relapsed Ewing Sarcoma
NCT03359005Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2018
- Primary completion
- Nov 2022
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in Ewing sarcoma, sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT03359005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359005.